Literature DB >> 2403571

Pathogenesis of the type 2 variant of the syndrome of apparent mineralocorticoid excess.

S Ulick1, R Tedde, F Mantero.   

Abstract

The syndrome of apparent mineralocorticoid excess, which is not a primary disorder of the adrenal cortex, describes the association of an unexplained hypermineralocorticoid state with a decreased rate of peripheral 11 beta-hydroxydehydrogenation of cortisol to cortisone. Studies in this syndrome have led to the hypothesis that peripheral cortisol inactivation is the normal mechanism permitting specific mineralocorticoid recognition. This view reconciled developing evidence that the mineralocorticoid receptor itself could not distinguish between mineralocorticoids and glucocorticoids. The syndrome occurs in two forms. In both forms there is decreased turnover of a normal level of plasma cortisol, consistent with the view that delayed removal of the glucocorticoid from strategic receptor sites unmasks its potential mineralocorticoid agonism. In the type 1 variant, impaired 11 beta-hydroxydehydrogenation is reflected by an elevated cortisol/cortisone metabolite ratio. In three patients with the type 2 variant, this ratio was normal, suggesting that the rate of 11 beta-hydroxydehydrogenation was unimpaired. The hypertension and hypokalemic alkalosis of both forms are improved by spironolactone, but patients with the type 2 variant have responded somewhat better to the suppression of cortisol by dexamethasone.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2403571     DOI: 10.1210/jcem-70-1-200

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Apparent mineralocorticoid excess syndromes.

Authors:  M Shimojo; P M Stewart
Journal:  J Endocrinol Invest       Date:  1995 Jul-Aug       Impact factor: 4.256

2.  Evidence for cortisol as the mineralocorticoid in the syndrome of apparent mineralocorticoid excess.

Authors:  R Tedde; A Pala; A Melis; S Ulick
Journal:  J Endocrinol Invest       Date:  1992-06       Impact factor: 4.256

3.  Hsd11b2 haploinsufficiency in mice causes salt sensitivity of blood pressure.

Authors:  Matthew A Bailey; Eilidh Craigie; Dawn E W Livingstone; Yuri V Kotelevtsev; Emad A S Al-Dujaili; Christopher J Kenyon; John J Mullins
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

4.  In silico structure-function analysis of pathological variation in the HSD11B2 gene sequence.

Authors:  Jonathan R Manning; Matthew A Bailey; Dinesh C Soares; Donald R Dunbar; John J Mullins
Journal:  Physiol Genomics       Date:  2010-06-22       Impact factor: 3.107

5.  Congenital deficiency of 11beta-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary free cortisol and cortisone.

Authors:  M Palermo; G Delitala; F Mantero; P M Stewart; C H Shackleton
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

6.  Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.

Authors:  A Li; R Tedde; Z S Krozowski; A Pala; K X Li; C H Shackleton; F Mantero; M Palermo; P M Stewart
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

7.  Failure to downregulate the epithelial sodium channel causes salt sensitivity in Hsd11b2 heterozygote mice.

Authors:  Eilidh Craigie; Louise C Evans; John J Mullins; Matthew A Bailey
Journal:  Hypertension       Date:  2012-07-09       Impact factor: 10.190

8.  Conditional Deletion of Hsd11b2 in the Brain Causes Salt Appetite and Hypertension.

Authors:  Louise C Evans; Jessica R Ivy; Caitlin Wyrwoll; Julie A McNairn; Robert I Menzies; Thorbjørn H Christensen; Emad A S Al-Dujaili; Christopher J Kenyon; John J Mullins; Jonathan R Seckl; Megan C Holmes; Matthew A Bailey
Journal:  Circulation       Date:  2016-03-07       Impact factor: 29.690

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.